Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1YOL

Crystal structure of Src kinase domain in complex with CGP77675

Summary for 1YOL
Entry DOI10.2210/pdb1yol/pdb
Related1YOJ 1YOM
DescriptorProto-oncogene tyrosine-protein kinase Src, 1-{4-[4-AMINO-5-(3-METHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL]BENZYL}PIPERIDIN-4-OL (3 entities in total)
Functional Keywordsprotein tyrosine kinase, transferase
Biological sourceHomo sapiens (human)
Cellular locationCell membrane: P12931
Total number of polymer chains2
Total formula weight65713.45
Authors
Breitenlechner, C.B.,Kairies, N.A.,Honold, K.,Scheiblich, S.,Koll, H.,Greiter, E.,Koch, S.,Schaefer, W.,Huber, R.,Engh, R.A. (deposition date: 2005-01-27, release date: 2006-01-27, Last modification date: 2023-10-25)
Primary citationBreitenlechner, C.B.,Kairies, N.A.,Honold, K.,Scheiblich, S.,Koll, H.,Greiter, E.,Koch, S.,Schaefer, W.,Huber, R.,Engh, R.A.
Crystal structures of active SRC kinase domain complexes
J.Mol.Biol., 353:222-231, 2005
Cited by
PubMed Abstract: c-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs. Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form. Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms. Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolutions ranging from 2.9A to 1.95A. The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation. The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340. In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.
PubMed: 16168436
DOI: 10.1016/j.jmb.2005.08.023
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.3 Å)
Structure validation

226707

건을2024-10-30부터공개중

PDB statisticsPDBj update infoContact PDBjnumon